Literature DB >> 15011999

The clades of HIV: their origins and clinical significance.

Justin Stebbing1, Graeme Moyle.   

Abstract

It is over 20 years since the identification of HIV as the causative agent of AIDS. Despite the innovation and perseverance of biomedical researchers, HIV has cumulatively infected over 60 million individuals and caused the deaths of over 28 million, the majority in the developing world. There is perhaps no greater need in medical science than the development of more effective treatments for HIV and, ultimately, a protective vaccine. The spread of an extraordinary range of variants of HIV has implications for diagnosis and therapy. As the availability of antiretrovirals increases, data on the clinical response to treatment for non-B subtype infections has increasing relevance. Efficient targeting of the extreme genetic diversity of HIV-1, and an understanding of the processes underlying this, represents one of the major challenges in the control of this ongoing pandemic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15011999

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  9 in total

Review 1.  Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative.

Authors:  Timothy J Tucker; Gatsha Mazithulela
Journal:  BMJ       Date:  2004-08-21

2.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.

Authors:  Sang-Kyung Lee; Derek M Dykxhoorn; Priti Kumar; Shahin Ranjbar; Erwei Song; Laura E Maliszewski; Vanessa François-Bongarçon; Anne Goldfeld; N Manjunath Swamy; Judy Lieberman; Premlata Shankar
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

3.  Phylogenetic analysis of the p24-p7 region of the human immunodeficiency virus type 1 gag gene to determine subtype distribution among female sex workers in Calcutta, India.

Authors:  Satarupa Sengupta; Smarajit Jana; Pratim Roy; Kamalesh Sarkar; Sujit K Bhattacharya; Sekhar Chakrabarti
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 4.  Lentiviral delivery of short hairpin RNAs.

Authors:  N Manjunath; Haoquan Wu; Sandesh Subramanya; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2009-03-31       Impact factor: 15.470

Review 5.  Critical issues in mucosal immunity for HIV-1 vaccine development.

Authors:  Barton F Haynes; Robin J Shattock
Journal:  J Allergy Clin Immunol       Date:  2008-05-12       Impact factor: 10.793

6.  High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.

Authors:  Marit J van Gils; Diana Edo-Matas; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  J Gen Virol       Date:  2009-09-30       Impact factor: 3.891

7.  Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.

Authors:  Darrell H S Tan; Janet M Raboud; Rupert Kaul; Beatriz Grinsztejn; Pedro Cahn; Sharon L Walmsley
Journal:  Trials       Date:  2010-11-24       Impact factor: 2.279

8.  Immunogenicity of the outer domain of a HIV-1 clade C gp120.

Authors:  Hongying Chen; Xiaodong Xu; Ian M Jones
Journal:  Retrovirology       Date:  2007-05-17       Impact factor: 4.602

9.  Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.

Authors:  Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Beatriz Grinsztejn; José Valdez Madruga; Maria Ines Figueroa; Pedro Cahn; Simon E Barton; Amanda Clarke; Julie Fox; Wendy Zubyk; Sharon L Walmsley
Journal:  J Antimicrob Chemother       Date:  2019-02-01       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.